Kyverna Therapeutics, Inc. KYTX
6.81
(0.18)
(2.58%)
as of 25 Sep
- Market cap
- $432.3M
- P/E
- 0.0×
Follow KYTX
Insider Buys
alert about insiders buying in the last 12 month
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
P/S ratio |
0.00 | — | — | — |
P/FCF ratio |
0.00 | — | — | — |
P/Operating CF |
(1.09) | — | — | — |
P/B ratio |
0.00 | — | — | — |
Price to Tangible BV |
0.00 | — | — | — |
EV/Sales |
0.00 | — | — | — |
EV/EBITDA |
0.60 | — | — | — |
EV/Operating CF |
0.69 | — | — | — |
EV/FCF |
0.69 | — | — | — |
Quick Ratio |
4.29 | 2.90 | 8.47 | 7.65 |
Current Ratio |
4.45 | 3.05 | 8.61 | 7.75 |
Net Debt/EBITDA |
1.77 | 0.93 | 2.03 | 1.51 |
Debt/Assets |
1.61% | 1.22% | 0.05% | 8.42% |
Debt/Equity |
(0.01) | (0.01) | 0.00 | 0.11 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.25 | 0.87 | 0.90 | 0.95 |
Capex/Depreciation |
(0.73) | (0.36) | (1.03) | 0.04 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | 58.78% | (188.59%) | (64.67%) | |
| 0.00% | (84.95%) | (67.12%) | (53.91%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(65.86%) | (139.96%) | (48.99%) | (65.04%) |
Average Days of Receivables |
0.00 | — | — | — |
Research and Development Expense of Revenue |
404.30% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
113.98% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
13.22% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(7.22) | — | — | — |
Graham Number |
0.00 | — | — | — |
Earnings Yield |
(298.55%) | — | — | — |
Free Cash Flow Yield |
(262.27%) | — | — | — |
Revenue per Share |
15.42 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(79.28) | (77.76) | (2.98) | (3.47) |
Capex per Share |
(1.69) | (0.92) | (0.06) | 0.00 |
Free Cash Flow per Share |
(80.97) | (78.68) | (3.04) | (3.47) |
Cash per Share |
112.67 | 85.38 | 7.46 | 6.31 |
Shareholders Equity per Share |
(162.45) | (194.95) | 6.95 | 5.25 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(162.45) | (194.95) | 6.95 | 5.25 |
Free Cash Flow |
(36.88) | (53.03) | (116.45) | (153.65) |
Working Capital |
41.30 | 40.81 | 256.85 | 246.47 |
Capital Expenditures |
(0.77) | (0.62) | (2.20) | 0.07 |
Net Current Asset Value |
(87.67) | (145.93) | 252.54 | 221.40 |
EV/EBIT |
0.58 | — | — | — |
Capex to Sales |
0.11 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
(411.29%) | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | — | — | — |
| Other line items | ||||
Depreciation/Fixed assets |
0.41 | 0.73 | 0.64 | 1.16 |
Cash ROIC |
179.14% | 75.05% | (21.28%) | (28.95%) |
Accounts Receivable Turnover |
0.00 | — | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 2.90 | 4.49 | 4.97 |
Average Assets |
— | 71.06 | 189.92 | 299.24 |
Average Common Equity |
— | (102.70) | 67.60 | 249.43 |
Columns are period end dates